Table 2.
Risk factors for rebleeding after discharge on univariate analysis (n = 132)
| Factor | Non-rebleeding/rebleeding | Hazard ratio (95%CI) | P |
| Age > 70 yr | 45 (48)/25 (64) | 1.6 (0.83-3.1) | 0.15 |
| Sex, male | 59 (63)/28 (72) | 1.1 (0.57-2.3) | 0.70 |
| Anatomical distribution of diverticula | |||
| Right-sided diverticula | 34 (37)/8 (21) | 0.49 (0.22-1.1) | 0.06 |
| Left-sided diverticula | 19 (20)/8 (21) | 1.3 (0.60-2.8) | 0.51 |
| Bilateral diverticula | 40 (43)/23 (59) | 1.5 (0.79-2.8) | 0.21 |
| Endoscopic procedure | 20 (22)/3 (7.7) | 0.43 (0.13-1.4) | 0.16 |
| Transfusion requirement | 25 (27)/12 (31) | 1.2 (0.63-2.5) | 0.53 |
| Current drinker | 90 (97)/36 (92) | 0.78 (0.24-2.5) | 0.68 |
| Current smoker | 26 (28)/10 (26) | 0.80 (0.39-1.7) | 0.55 |
| NSAID users | 4 (4.3)/11 (28) | 5.1 (2.5-10) | < 0.01 |
| Low-dose aspirin1 users | 20 (22)/9 (23) | 0.88 (0.42-1.9) | 0.74 |
| Non-aspirin antiplatelet1 users | 16 (17)/11 (28) | 1.6 (0.78-3.1) | 0.21 |
| Anticoagulant1 users | 7 (7.5)/2 (5.1) | 0.54 (0.13-2.2) | 0.38 |
| Acetaminophen users | 10 (11)/3 (7.7) | 0.72 (0.22-2.3) | 0.58 |
| Corticosteroid users | 3 (3.2)/2 (5.1) | 1.4 (0.35-6.0) | 0.61 |
| Hypertension | 55 (60)/28 (72) | 1.4 (0.69-2.8) | 0.35 |
| Diabetes mellitus | 22 (24)/5 (13) | 0.52 (0.20-1.3) | 0.16 |
| Dyslipidemia | 20 (22)/9 (23) | 0.88 (0.42-1.8) | 0.73 |
| Cardiovascular disease | 25 (27)/8 (21) | 0.55 (0.25-1.2) | 0.13 |
| Cerebrovascular disease | 1 (1.1)/1 (2.6) | 1.4 (0.19-10) | 0.76 |
| Chronic liver disease | 3 (3.2)/2 (5.1) | 1.4 (0.34-5.9) | 0.62 |
| Hemodialysis | 2 (2.2)/5 (13) | 4.0 (1.5-10) | < 0.01 |
Non-selective NSAIDs included loxoprofen, diclofenac, naproxen, etodolac, zaltoprofen, meloxicam, lornoxicam, and celecoxib (n = 3). Distribution type was defined as follows: right-sided, involving the transverse or proximal colon; left-sided, involving the descending or distal colon; or bilateral, involving the entire colon. Low-dose aspirin included enteric-coated aspirin (100 mg) and buffered aspirin (81 mg). Non-aspirin antiplatelets included ticlopidine, clopidogrel, cilostazol, dipyridamole, sarpogrelate hydrochloride, ethyl icosapentate, dilazep, limaprost, and beraprost. Anticoagulants included warfarin and dabigatran etexilate. CI: Confidence interval; NSAIDs: Non-steroidal anti-inflammatory drugs.